Literature DB >> 22076508

Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.

Da Pang1, Yashuang Zhao, Weinan Xue, Ming Shan, Yanbo Chen, Youxue Zhang, Guoqiang Zhang, Feng Liu, Dalin Li, Yanmei Yang.   

Abstract

The development of breast cancer is a multistep process associated with complex changes in host gene expression patterns including inactivation of tumor suppressor genes and activation of oncogenes. Critically, hereditary predisposition plays a significant role in cancer susceptibility. However, mutation of the BRCA1 gene is found only in the minority of hereditary breast cancer, which indicates that there might be alternative, novel mechanisms contributing to inactivation of the BRCA1 gene. Studies have shown that aberrant methylation of genomic DNA plays an important role in carcinogenesis. The aim of this study was to investigate whether DNA methylation may be an alternative mechanism for the inactivation of BRCA1 as an epigenetic modification of the genome and whether hereditary breast cancer has a different BRCA1 methylation phenotype pattern than sporadic breast cancer. The pattern of CpG island methylation within the promoter region of BRCA1 was assessed by bisulfite sequencing DNA from peripheral blood cells of 72 patients with hereditary predisposition but without BRCA1 mutations and 30 sporadic breast cancer controls. The overall methylation level in patients with hereditary predisposition was significantly lower than that in the sporadic control group. However, patients with hereditary predisposition showed a significantly higher methylation susceptibility for the sites -518 when compared to controls. These results suggest that there might be different BRCA1 promoter methylation levels and patterns in sporadic and hereditary breast cancer in peripheral blood DNA. These findings may facilitate the early diagnosis of hereditary breast cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22076508     DOI: 10.1007/s12032-011-0100-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.

Authors:  Ying Chen; Amanda E Toland; Jane McLennan; Jane Fridlyand; Beth Crawford; Joseph F Costello; John L Ziegler
Journal:  Genet Test       Date:  2006

2.  Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases.

Authors:  M Okano; S Xie; E Li
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

3.  Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours.

Authors:  Azhar B Ali; Philip T C Iau; Jen-Hwei Sng
Journal:  Med Oncol       Date:  2010-02-05       Impact factor: 3.064

4.  Sp1 binding is inhibited by (m)Cp(m)CpG methylation.

Authors:  S J Clark; J Harrison; P L Molloy
Journal:  Gene       Date:  1997-08-11       Impact factor: 3.688

Review 5.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

6.  CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.

Authors:  D N Mancini; D I Rodenhiser; P J Ainsworth; F P O'Malley; S M Singh; W Xing; T K Archer
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

Review 7.  DNA methylation: a promising target for the twenty-first century.

Authors:  Paula A Abreu; Gisela Dellamora-Ortiz; Luiz R Leão-Ferreira; Maria Gouveia; Esteban Braggio; Ilana Zalcberg; Dilvani O Santos; Saulo Bourguinhon; Lucio M Cabral; Carlos R Rodrigues; Helena C Castro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

8.  Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry.

Authors:  Hulya Yazici; Mary Beth Terry; Yoon Hee Cho; Ruby T Senie; Yuyan Liao; Irene Andrulis; Regina M Santella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-15       Impact factor: 4.254

9.  Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

Authors:  K P M Suijkerbuijk; M J Fackler; S Sukumar; C H van Gils; T van Laar; E van der Wall; M Vooijs; P J van Diest
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

Review 10.  DNA methylation in cancer: too much, but also too little.

Authors:  Melanie Ehrlich
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

View more
  7 in total

1.  Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

2.  Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.

Authors:  M Rodríguez-Balada; B Roig; M Melé; M Salvat; L Martorell; J Borràs; J Gumà
Journal:  Clin Transl Oncol       Date:  2018-02-05       Impact factor: 3.405

3.  BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.

Authors:  Amanjit Bal; Sangeeta Verma; Kusum Joshi; Anuj Singla; Ravi Thakur; Sunil Arora; Gurpreet Singh
Journal:  Virchows Arch       Date:  2012-07-21       Impact factor: 4.064

Review 4.  DNA methylation as a promising landscape: A simple blood test for breast cancer prediction.

Authors:  Golnaz Khakpour; Arash Pooladi; Pantea Izadi; Mehrdad Noruzinia; Javad Tavakkoly Bazzaz
Journal:  Tumour Biol       Date:  2015-06-16

Review 5.  Epigenetic changes in BRCA1-mutated familial breast cancer.

Authors:  Bradley Downs; San Ming Wang
Journal:  Cancer Genet       Date:  2015-02-13

6.  Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.

Authors:  Bàrbara Roig; Marta Rodríguez-Balada; Sara Samino; Eric W-F Lam; Sandra Guaita-Esteruelas; Ana R Gomes; Xavier Correig; Joan Borràs; Oscar Yanes; Josep Gumà
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

7.  Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.

Authors:  Sarah L Daniels; George J Burghel; Philip Chambers; Shadi Al-Baba; Daniel D Connley; Ian W Brock; Helen E Cramp; Olena Dotsenko; Octavia Wilks; Lynda Wyld; Simon S Cross; Angela Cox
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.